Compliance with contraceptives and other treatments

Obstetrics and Gynecology

Volumn 88, Issue 3 SUPPL., 1996, Pages 4S-12S

  Cramer, Joyce A ^a  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; ESTRADIOL; ESTROGEN; GEMFIBROZIL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AMENORRHEA; BIRTH CONTROL; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTRACEPTIVE DEVICE; DRUG EFFICACY; DRUG LABELING; ELECTRONICS; FATIGUE; FEMALE; HEADACHE; HUMAN; MASTALGIA; NAUSEA; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VERTIGO;

EID: 0029788325     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(96)00248-7     Document Type: Article

References (42)

1. McCann MF, Potter LS. Progestin-only oral contraception: A comprehensive review. Contraception 1994;50(suppl 1):S9-195.
2. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:195-207.
3. Grady WR, Hayward MD, Yagi J. Contraceptive failure in the United States: Estimates from the 1982 National Survey of Family Growth. Fam Plann Perspect 1986;18:200-9.
4. Emans SJ, Grace E, Woods ER, Smith DE, Klein K, Merola J. Adolescent's compliance with the use of oral contraceptives. JAMA 1987;257:3377-81.
5. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:10-24.
6. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68.
7. Green LW, Dolan PD, Friedman RB. Epidemiological and community approaches to patient compliance. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:373-86.
8. Cramer JA. Identifying and improving compliance patterns: A composite plan for health care providers. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:387-92.
9. Cramer JA. Feedback on medication dosing enhances patient compliance. Chest 1993;104:333-4.
10. Cramer JA. Overview of methods to measure and enhance patient compliance. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:3-10.
11. Cramer JA. The relationship between medication compliance and medical outcomes. Am J Health Syst Pharm 1995;52(suppl 3): S27-9.
12. LRC-CPPT. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251: 365-74.
13. Lasagna L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:393-404.
14. Maenpaa H, Manninen V, Heinonen OP. Compliance with medication in the Helsinki Heart Study. Eur J Clin Pharmacol 1992;42: 15-9.
15. Cramer JA, Mattson RH, Prevey ML, Scheyer R, Ouellette V. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
16. Sherbourne CD, Hays RD, Ordway L. Antecedents of adherence to medical recommendations: Results from the Medical Outcomes Study. J Behav Med 1992;15:447-68.
17. Jones EE. Androgenic effects of oral contraceptives: Implications for patient compliance. Am J Med 1995;98(suppl 1A):116S-9S.
18. Pratt WR, Bachrach CA. What do women use when they stop using the pill? Fam Plann Perspect 1987;19:257-66.
19. Balassone ML. Risk of contraceptive discontinuation among adolescents. J Adolesc Health Care 1989;10:527-33.
20. Cromer B. Behavioral strategies to increase compliance in adolescents. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:99-105.
21. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. Int Clin Psychopharmacol 1995;9(suppl 4):33-40.
22. Schweitzer RT, Rovelli M, Palmieri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation 1990;49:374-7.
23. Montgomery SB, Joseph JG, Becker MH, Ostrow DG, Kessler RC, Kirscht JP. The Health Belief Model in understanding compliance with preventive recommendations for AIDS: How useful? AIDS Educ Prev 1989;1:303-23.
24. Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991.
25. Cramer JA, Collins JF, Mattson RH. Can categorization of patient background problems be used to determine early termination in a clinical trial? Controlled Clin Trials 1988;9:47-63.
26. Baekeland F, Lund L. Dropping out of treatment: A critical review. Psychol Bull 1975;82:738-83.
27. Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:123-38.
28. Morris LS, Schulz RM. Patient compliance - an overview. J Clin Pharm Ther 1992;17:283-95.
29. Jay MS, DuRant RH, Shoffitt T, Linder CW, Litt IF. Effects of peer counselors on adolescent compliance in use of oral contraceptives. Pediatrics 1984;73:126-31.
30. Hulka BS, Kupper LL, Cassel JC, Efird RL, Burdette JA. Communication, compliance, and concordance between physicians and patients with their prescribed medicines. Am J Public Health 1976;66:847-53.
31. Rovelli M, Palmieri D, Vossler E, Bartus S, Hull D, Schweitzer R. Noncompliance in organ transplant recipients. Transplant Proc 1989;21:833-4.
32. Cromer BA, Smith RD, McArdle Blair J, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994;94:687-94.
33. Darney P, Atkinson E, Swift A, Colacurcio V. Am J Public Health (in press).
34. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332: 1125-31.
35. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology 1984;34:1255-8.
36. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:238-40.
37. Rudd P, Byyny RL, Zachary V, LoVerde ME, Mitchell WD, Titus C. Pill count measures of compliance in a drug trial: Variability and suitability. Am J Hypertens 1988;1:309-12.
38. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989;46:163-8.
39. Gonder-Frederick LA, Julian DM, Cox DJ, Clarke WL, Carter WR. Self-measurement of blood glucose: Accuracy of self-reported data and adherence to recommended regimen. Diabetes Care 1988;2: 579-85.
40. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther 1994;16:316-26.
41. Cramer JA, Scheyer R, Mattson R. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-10.
42. Gerlach J. Depot neuroleptics in relapse prevention: Advantages and disadvantages. Int Clin Psychopharmacol 1995;9(suppl 5): 17-20.